Status:
COMPLETED
Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients
Lead Sponsor:
Echosens
Conditions:
Liver Fibrosis
Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients \> 28 kg/m² with various liver diseases in...
Eligibility Criteria
Inclusion
- Patient of at least 18 years of age
- Patient able to give written informed consent form
- Patient with a BMI superior or equal to 28kg/m²
- Patient scheduled to have a liver biopsy within 1 month after the enrollment or with a liver biopsy performed within 6 months before the enrollment.
- Patient for which abdominal ultrasound is technically possible
Exclusion
- Unable or unwilling to provide written informed consent
- Confirmed diagnosis and/or history of malignancy, or other terminal disease
- Patients with clinical ascites
- Pregnant women
- Patient with a BMI \< 28 kg/m²
- Patients with any active implantable medical device (such as pacemaker or defibrillator)
- Transplanted patient and patient with heart disease
- Refusal to undergo a liver biopsy
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00926224
Start Date
July 1 2009
End Date
September 1 2010
Last Update
November 16 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Calgary University Hospital
Calgary, Alberta, Canada, T2N 4N
2
London University Hospital
London, Ontario, Canada, N6A 5A5
3
Toronto Western General Hospital
Toronto, Ontario, Canada, M5T 2S8
4
Toronto Liver Centre
Toronto, Ontario, Canada, M6H 3M1